Medical Specialty >> Pharmacy
FDA Halts All Sales of Pelvic Mesh Products Tied to Injuries in Women
2:00 PM CDT.
Read article
- Another Cost of the Opioid Epidemic: Billions of Dollars in Lost Taxes
- ‘Added Sugars’ Label on Foods Could Save Many Lives
- FDA Orders Label Warning on Alcohol Use With ‘Female Viagra’
- Americans Are Dying From Kratom Overdoses: CDC
JOURNAL UPDATE
UB-421 Monotherapy Maintains HIV Viral Suppression
12:00 PM CDT. Suppression maintained for up to 16 weeks in HIV-infected undergoing analytic treatment interruption- Some Patients With Imminently Fatal Cancer Undergo Treatment
- Parenteral Antimicrobial Tx at Home Burdens Children’s Caregivers
- Intensive BP Lowering May Up Cognitive Decline in Elderly
MONTHLY JOURNAL SUMMARY
March 2019 Briefing - Pharmacy
April 01, 2019. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
Ted Lain, MD.
Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,…
Bevacizumab for breast cancer: FDA grants a stay of execution
Dr. Alberto De la Guerra.
The Food and Drug Administration has after repeated delays proposed removing metastatic breast cancer as an indication from the Avastin label. The proposal is being contested by Roche/Genentech, the drug’s maker. In this article we review the evidence for and against this decision.
MEDICAL FOCUS
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By MrRobinGreat articles. learnt a lot from it.
